A Phase II, Randomized, Double-Blind, Cross-Over Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-Glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
Latest Information Update: 12 Jan 2026
At a glance
- Drugs Ensifentrine/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Verona Pharma
Most Recent Events
- 08 Jan 2026 Status changed from active, no longer recruiting to completed.
- 28 Oct 2025 Planned End Date changed from 23 Feb 2026 to 9 Dec 2025.
- 28 Oct 2025 Planned primary completion date changed from 23 Feb 2026 to 9 Dec 2025.